ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
65 announcements with these filters
Mankind Pharma's FY25 ESG report highlights a 73% carbon reduction since FY21 and 63% renewable energy mix. The company is focused on embedding sustainable practices across manufacturing and its value chain.
Mankind Pharma approved a ₹150 Crore corporate guarantee in favour of banks for Bharat Serums and Vaccines Limited's credit facilities. This contingent liability supports BSV's operations.
Mankind Pharma reported Q1 FY27 revenue of ₹4,031 crore, up 12.9% YoY. EBITDA grew 24.7% to ₹1,060 crore, with a margin of 26.3%.
Mankind Pharma reported strong Q1 FY27 results with 12.9% revenue growth and 29.1% PAT growth. Strategy focuses on chronic segment expansion, BSV integration, and OTC growth.
Mankind Pharma Ltd reported revenue from operations of ₹4,031 Cr (+12.9% YoY) and net profit of ₹574.1 Cr (+29.1% YoY) for Q1 FY27.
Mankind Pharma has completed the sale of its 100% stake in Broadway Hospitality Services Private Limited for a cash consideration of ₹ 49 Crore.
Mankind Pharma Ltd filed its quarterly shareholding pattern under Regulation 31(1)(b) with the exchange. This is a standard periodic disclosure of the company's ownership structure.
Mankind Pharma will hold a board meeting on July 30, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Mankind Pharma will sell its subsidiary Broadway Hospitality Services to AKRK Projects for ₹49 Crore. The cash deal is expected to conclude by October 2026.
Mankind Pharma will incorporate a wholly-owned subsidiary in Netherlands with a 54 Crore investment. The entity will hold R&D assets and pursue niche therapy joint ventures.
Mankind Pharma approved divesting 100% stake in Broadway Hospitality for Rs. 49 Crore. It also plans to invest €5 Million to incorporate a new Netherlands-based subsidiary.
Mankind Pharma Limited submitted its Business Responsibility & Sustainability Report for FY 2025-26. The report details the company's environmental, social, and governance performance metrics.
Mankind Pharma has scheduled its 35th AGM for August 4, 2026, via video conferencing. The company also released its Annual Report for FY 2025-26.
Mankind Pharma Ltd will hold its 35th Annual General Meeting on August 4, 2026 via video conference. Notice and the annual report will be sent to members.
Mankind Pharma appointed Nilesh Kulkarni as Head of HR and Senior Management Personnel. Prateek Dubey transitions to new responsibilities, effective June 8, 2026, amid organizational restructuring.
Mankind Pharma allotted 86,778 equity shares under its ESOP scheme. This increases the total paid-up share capital to 412,995,978 equity shares.
Mankind Pharma allotted 86,778 equity shares worth ₹7.50 Crore under its 2022 ESOP Plan. The allotment increases the company's total paid-up equity share capital.
Mankind Pharma's subsidiary acquired the remaining 10% stake in Upakarma Ayurveda for ₹0.75 Crore. This transaction makes Upakarma a wholly-owned step-down subsidiary to improve operational efficiencies.
Mankind Pharma reported strong Q4 FY26 results with 11.8% revenue growth and 27.1% EBITDA margins, driven by chronic therapy outperformance and steady recovery in acute segments.
Mankind Pharma announced the re-appointment of WTD Satish Kumar Sharma and the resignation of SMP Pramod Gokhale. These changes reflect standard corporate governance and leadership transitions.
Mankind Pharma approved a ₹500 Crore investment in its subsidiary, Mankind Medicare, for capacity expansion. The capital will fund a new pharmaceutical manufacturing plant.
Mankind Pharma allotted 80,872 equity shares under its employee stock option scheme. Post-allotment, the company's paid-up share capital increased to 412,909,200 equity shares.
Mankind Pharma reported FY26 revenue of ₹14,278 Crore, up 17% YoY. Q4FY26 adjusted EBITDA margins reached 27.1%, driven by strong domestic chronic and OTC growth.
Mankind Pharma reported ₹14,278 Cr FY26 revenue, focusing on increasing chronic share (39.9% in Q4) and super-specialty expansion via BSV acquisition.
Mankind Pharma allotted 80,872 equity shares worth ₹7.51 Crore under its ESOP 2022 plan. This exercise increases the company's paid-up share capital to 41,29,09,200 shares.
Mankind Pharma Ltd reported revenue from operations of ₹3,443 Cr (+11.8% YoY) and net profit of ₹559.4 Cr (+31.7% YoY) for Q4 FY26.
Mankind Pharma approved its audited FY26 results, reporting consolidated annual revenue of ₹14,277.64 Crore. The Board also cleared a ₹500 Crore investment in its Medicare subsidiary.
ICRA reaffirmed Mankind Pharma's AA+ ratings and assigned A1+ for ₹6,850 Crore in debt instruments. The stable outlook reflects the company's robust credit profile.
Mankind Pharma scheduled a board meeting on May 19, 2026. Directors will approve FY26 audited results and realignment of security cover for existing NCDs.
Mankind Pharma Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. Issued by M/s Amit Gupta & Associates, the report confirms the company's adherence to SEBI regulations and statutory provisions. This filing is a routine regulatory requirement for listed entities in India.